Working-class men diagnosed with prostate cancer are disproportionately affected by the current NHS system, according to new data. While national mortality rates from the disease have decreased across England since 2016, improvements in affluent areas far outpace those in more deprived regions.
Deaths per 100,000 men fell nationally from 47.72 in 2016–2018 to 43.68 in 2021–2023. However, the gap between wealthy and deprived areas has widened, with the most deprived communities recording 45.94 deaths per 100,000 men, compared with 42 per 100,000 in affluent regions. This disparity of nearly four points is more than double the initial gap recorded.
Calls for Targeted Screening
Experts emphasize the importance of proactive prostate cancer screening. Men in wealthier areas are more likely to know they can request a prostate-specific antigen (PSA) test from their GP, leading to earlier detection and improved outcomes.
The Telegraph has campaigned for a targeted screening programme to ensure high-risk groups, including black men and those with a family history of the disease, are offered tests systematically. The UK National Screening Committee is reviewing the evidence for such an approach, having previously rejected it due to concerns about PSA test reliability.
Recent research suggests that screening, especially when combined with MRI scans to confirm diagnoses, can effectively identify cases that require treatment.
Ethnic and Socioeconomic Inequalities
Black men are twice as likely to develop prostate cancer and twice as likely to die from it, research shows. These populations are disproportionately represented in deprived areas, compounding the inequities in detection and treatment.
Professor Nick James, of The Institute of Cancer Research, London, explained: “Middle-class men are far more likely to come forward for tests, while working-class men are left behind. This data highlights a major inequality, particularly affecting ethnic minorities who are at higher risk and often live in deprived communities.”
David James, director of patient projects at Prostate Cancer Research, echoed these concerns: “Men from privileged backgrounds, often better equipped to navigate the healthcare system, have the best chances of survival. Black men and those with a family history face the highest risks, yet under the current system, they benefit the least. A targeted screening programme is urgently needed to ensure survival is not determined by postcode or background.”
Regional Disparities in Mortality
The new data from the Government’s Office for Health Improvement and Disparities (OHID) show stark regional differences. West Lindsey in Lincolnshire recorded the highest mortality rate at 62.1 deaths per 100,000 men, followed by Ashfield in Nottinghamshire (59.3) and Dartford in Kent (57.9). Conversely, Surrey Heath (25.4), Barnet (26.7), and Three Rivers (29) reported the lowest rates.
Earlier research published in BMJ Oncology also highlighted geographic disparities in terminal prostate cancer diagnoses. Patients in Devon and Cornwall fared worst, followed by Yorkshire, the North East, and Cumbria, while London, Kent, Dorset, Hampshire, and the Isle of Wight had the best outcomes.
Government Response
A spokesperson for the Department of Health and Social Care stated: “Life chances should never be determined by where you live, which is why we are prioritising investment in areas with the greatest health needs. The UK National Screening Committee is reviewing prostate cancer screening for high-risk groups, including those with a family history. Alongside this, we are investing £16 million in innovative detection trials and deploying cutting-edge technology to personalise medicine, detect disease earlier, and save lives.”
Conclusion
The current data highlights a pressing need for action to reduce socioeconomic and ethnic inequalities in prostate cancer outcomes. Experts and patient advocates agree that without targeted interventions, men in deprived communities will continue to face higher mortality rates, underscoring the critical role of proactive screening and education to ensure equitable access to early detection and treatment.
Related topics
